Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Harvard Drug Continues Expansion With Watson’s Rugby OTC Business

This article was originally published in The Tan Sheet

Executive Summary

Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.

You may also be interested in...



Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight

Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.

Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight

Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.

In Brief

Lawmakers push energy drink investigation; Innophos buys Triarco; BASF sweetens Pronova bid; meclizine mix-up spurs iron supplement recall; Abbott Nutrition margin growth on track; Neptune’s struggles continue; Vitamin Shoppe reaches Canada; more news In Brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel